Innovotech Inc. (TSXV: IOT), a Canadian contract research organization specializing in biofilm science and antimicrobial testing, announced its intention to obtain a stock quotation on the OTCQB Venture Market in the United States. The move is designed to enhance the company's visibility among U.S. investors and improve liquidity for its common shares. The OTCQB quotation will operate in parallel with Innovotech's primary listing on the TSX Venture Exchange and is not expected to impose any additional material compliance or reporting requirements.
As a foreign private issuer, Innovotech will continue to meet its existing primary market disclosure obligations on SEDAR+, which satisfy OTC market requirements under established foreign issuer exemptions. To be eligible for the OTCQB, companies must meet certain financial standards, remain current in their reporting, and undergo an annual verification and management certification process. In conjunction with the listing, Innovotech will also apply for eligibility with the Depository Trust Company (DTC), which would enable simplified electronic clearing and settlement of its shares for U.S. investors.
The OTCQB is a venture market designed for early-stage and developing U.S. and international companies. By listing on this platform, Innovotech aims to make its stock more accessible to retail and institutional investors in the United States, potentially increasing trading volume and shareholder base. The company, headquartered in Edmonton, Alberta, operates ISO-certified and GMP-accredited laboratories and serves clients across multiple sectors, including pharmaceutical, industrial, and regulatory agencies.
Innovotech's core expertise lies in biofilm science, and it commercializes the MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. The company provides advanced laboratory services, including antimicrobial testing, pharmaceutical analysis, and industrial solutions, meeting rigorous standards such as those of the U.S. Food and Drug Administration and Health Canada. More information about the company is available at https://www.innovotech.ca.
The announcement underscores Innovotech's strategic efforts to expand its investor reach beyond Canada. By securing a U.S. quotation and DTC eligibility, the company expects to streamline the investment process for American shareholders, potentially attracting greater interest from the broader investment community. The company's forward-looking statements caution that actual results may differ materially due to risks including regulatory outcomes, currency fluctuations, reliance on a small customer base, and intellectual property challenges. Further details are available in the original press release on www.newmediawire.com.
